| Publisher's Note |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Clinical Ovarian … & Other Gynecologic Cancer Too!
Clinical Ovarian Cancer & Other Gynecologic Malignancies has always sought to evolve along with the interests of our readership. Since our debut in June 2008, we have striven to provide physicians...
|
David M. Allen
|
53
|
|
| Expert Panel |
| |
Article Title |
Author(s) |
Pages |
|
|
|
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
Ovarian cancers are the second most frequent group of invasive malignancies of the female genital tract (an estimated 21,650 new cases in 2008); however, the lack of an effective early diagnostic test...
|
J. Tate Thigpen
|
54-56
|
|
|
|
CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
Ovarian cancer remains an important health problem for women in the United States. It is estimated that there will be 21,650 cases of invasive ovarian cancer resulting in 15,520 deaths in 2008. Ovaria...
|
John Farley,
Michael J. Birrer
|
57-61
|
|
|
|
PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy
Patients with endometrial carcinoma involving extrauterine disease should, after any indicated surgery, receive chemotherapy. The following discussion supports the pro side of this thesis. To determin...
|
J. Tate Thigpen
|
62-65
|
|
|
|
CON: Not All Patients With Endometrial Cancer With Extrauterine Disease Should Receive Chemotherapy After Any Indicated Surgery
The adoption of primary surgical therapy and staging (including lymph node assessment and/or dissection) has given us a better understanding of prognostic groups, risk factors, and patterns of recurre...
|
Marcus E. Randall
|
66-69
|
|
|
|
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
Ovarian cancer remains a serious health problem for women in the United States. The American Cancer Society estimates that 21,650 women will be diagnosed with ovarian cancer in 2008.1 Of the 28,490 de...
|
David Boruta,
John Farley,
Michael J. Birrer
|
70-73
|
|
|
|
CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy
The following discussion argues against the assertion that patients with recurrent ovarian cancer should routinely receive anti-angiogenic agents in combination with chemotherapy. In order to support ...
|
Paul Sabbatini
|
74-76
|
|
|
|
PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
While cytoreductive surgery and platinum-based chemotherapy remain mainstays of the primary treatment of epithelial ovarian cancer, > 60% of patients will be diagnosed with a recurrence. Despite th...
|
Christa I. Nagel,
Matthew J. Carlson,
Larry J. Copeland
|
77-79
|
|
|
|
CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Cancer of the ovary is the eighth most common invasive malignancy of women and accounts for over half of the deaths related to gynecologic cancer the United States. Over 90% of these cases arise from ...
|
J. Tate Thigpen
|
80-82
|
|
|
|
PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening
Ovarian cancer remains the most lethal of all the gynecologic cancers. This is due in large part to the stage distribution of ovarian cancer. At the current time, over two thirds of patients have late...
|
Beth Y. Karlan
|
83-85
|
|
|
|
CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening
Ovarian cancer represents a significant and continuing health problem among women. For 2009, the American Cancer Society estimates that 21,550 women in the United States will have been newly diagnosed...
|
Thomas P. McNally,
Michael J. Birrer
|
86-89
|
|
|
|
PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel
Invasive cervical cancer was once one of the most common malignancies to affect women in the United States. Although it remains a worldwide epidemic with greater than 500,000 new cases diagnosed annua...
|
Krishnansu S. Tewari
|
90-93
|
|
|
|
CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel
The success of assessment of cervical cytology as a screening test for carcinoma of the uterine cervix has markedly reduced the number of deaths caused by this cancer in developed countries such as th...
|
J. Tate Thigpen
|
94-96
|
|
|
|
PRO: Systemic Therapy for All Endometrial Cancers Should be Paclitaxel Plus Carboplatin
The American Cancer Society estimates that approximately 1 in 40 women in the United States will develop uterine cancer during their lifetime. The majority of the patients diagnosed with endometrial c...
|
Matthew A. Powell
|
97-100
|
|
|
|
CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin
The thesis of the pro side of this debate is that systemic therapy for all endometrial carcinomas should be paclitaxel/carboplatin. To determine whether this thesis is true and is consistent with the ...
|
J. Tate Thigpen
|
101-105
|
|
|
|
PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
Uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) represent 2 rare endometrial cancer subtypes with significantly worse outcomes than the more common endometrioid endom...
|
Todd P. Boren,
David S. Miller
|
106-110
|
|
|
|
CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
Although endometrial cancer is the most common gynecologic malignancy among women in the United States, serous and clear cell carcinomas are less common and more virulent histologic types. Uterine pap...
|
Eric L. Eisenhauer
|
111-113
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
A1
|
|
|
|
Table of Contents
|
|
A2-A3
|
|
